See also separate profile for ivacaftor.
Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- Trade Name: Symdeko (Vertex)
- Indications: Cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene
- Class: CFTR potentiator (ivacaftor), CFTR protein corrector (tezacaftor)
- Half-life: 15 hours (tezacaftor); 14 hours (ivacaftor)
- FDA Approval Date: 02/12/2018
- Clinically important, potentially hazardous interactions with:
Carbamazepine, Clarithromycin, Erythromycin, Fluconazole, Grapefruit Juice, Itraconazole, Ketoconazole, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Seville oranges, St John's Wort, Strong CY3PA inducers, Strong or moderate CYP3A inhibitors, Telithromycin, Voriconazole - Pregnancy: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
